Comparison of Liver Health in Psoriatic Arthritis Patients Using Anti-TNF or Anti-IL17 Treatments

Launched by BEZMIALEM VAKIF UNIVERSITY · Apr 7, 2025

Keywords

ClinConnect Summary

This clinical trial is looking to compare liver health in patients with psoriatic arthritis (PsA) who are being treated with different types of medications. Specifically, the study will focus on patients using two kinds of biological treatments—anti-TNF and anti-IL-17 inhibitors—and see how these impact liver health over time. It aims to find out if these treatments lead to liver issues like scarring (called fibrosis) or fatty liver disease compared to patients who are only using methotrexate, a common medication for PsA.

To participate in this study, individuals need to be between 18 and 65 years old, diagnosed with psoriatic arthritis, and have been receiving one of the biological therapies or methotrexate for at least two years. They'll be asked to share their past medical records, including any liver tests they've had. The study will use non-invasive tests, like liver ultrasounds, to assess liver health. This research is important because it can help us understand whether newer treatments have better or worse effects on liver health compared to traditional therapies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 to 65 years
• • Diagnosed with psoriatic arthritis (PsA) according to standard classification criteria
• • Receiving biologic therapy (anti-TNF or anti-IL-17) or MTX monotherapy for ≥2 years
• • Able to provide historical data (medical records) on liver ultrasound and laboratory parameters
• Exclusion Criteria:
• • History of any other chronic liver disease (e.g., viral hepatitis, autoimmune hepatitis)
• • Significant alcohol consumption (\>20 g/day women, \>30 g/day men)
• • Concomitant use of other hepatotoxic drugs apart from MTX
• • Unwillingness or inability to comply with study assessments